ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences (RSLS) has been granted Patent Number 277949 in Israel for its Diabetes Neuromodulation technology, providing protection until December 4, 2039. The technology combines the company's proprietary vagus nerve block (vBloc™) platform with vagus nerve stimulation to treat Type 2 diabetes.
The system aims to reduce diabetics' medication dependence through personalized treatment, potentially lowering costs and complications associated with poor blood glucose control. The technology is supported by a strong intellectual property portfolio of 62 issued or pending patents related to vagal neuromodulation, glucose control, AI, and Bluetooth applications.
Pre-clinical development has been completed, demonstrating increased glycemic control in both Zucker rat and alloxan treated swine models of Type 2 Diabetes Mellitus (T2DM). The technology works by selectively modulating vagal block and stimulation to the liver and pancreas.
ReShape Lifesciences (RSLS) ha ottenuto il numero di brevetto 277949 in Israele per la sua tecnologia di neuromodulazione per il diabete, che fornisce protezione fino al 4 dicembre 2039. La tecnologia combina la piattaforma proprietaria di blocco del nervo vago (vBloc™) dell'azienda con la stimolazione del nervo vago per trattare il diabete di tipo 2.
Il sistema punta a ridurre la dipendenza dai farmaci per i diabetici attraverso un trattamento personalizzato, potenzialmente abbassando i costi e le complicazioni associate a un cattivo controllo della glicemia. La tecnologia è supportata da un forte portafoglio di proprietà intellettuale di 62 brevetti rilasciati o in attesa relativi alla neuromodulazione vagale, al controllo della glicemia, all'IA e alle applicazioni Bluetooth.
Lo sviluppo preclinico è stato completato, dimostrando un miglioramento del controllo glicemico sia nei modelli di ratto Zucker sia in quelli suini trattati con allossano di diabete mellito di tipo 2 (T2DM). La tecnologia funziona modulando selettivamente il blocco e la stimolazione vagali al fegato e al pancreas.
ReShape Lifesciences (RSLS) ha recibido la patente número 277949 en Israel por su tecnología de neuromodulación para la diabetes, ofreciendo protección hasta el 4 de diciembre de 2039. La tecnología combina la plataforma propietaria de bloqueo del nervio vago (vBloc™) de la empresa con la estimulación del nervio vago para tratar la diabetes tipo 2.
El sistema tiene como objetivo reducir la dependencia de los medicamentos en los diabéticos a través de un tratamiento personalizado, lo que potencialmente reduce costos y complicaciones asociadas con un mal control de la glucosa en sangre. La tecnología cuenta con un sólido portafolio de propiedad intelectual de 62 patentes otorgadas o pendientes relacionadas con la neuromodulación vagal, el control de la glucosa, la IA y las aplicaciones Bluetooth.
El desarrollo preclínico se ha completado, demostrando un mayor control glicémico tanto en modelos de ratas Zucker como en modelos porcinos tratados con aloxano de diabetes mellitus tipo 2 (T2DM). La tecnología funciona modulando selectivamente el bloqueo y la estimulación vagal en el hígado y el páncreas.
ReShape Lifesciences (RSLS)는 이스라엘에서 당뇨병 신경 조절 기술에 대한 특허번호 277949를 받았으며, 이는 2039년 12월 4일까지 보호됩니다. 이 기술은 회사의 독자적인 미주신경 차단(vBloc™) 플랫폼과 미주신경 자극을 결합하여 제2형 당뇨병을 치료합니다.
이 시스템은 개인화된 치료를 통해 당뇨환자의 약물 의존성을 줄이는 것을 목표로 하며, 이는 나쁜 혈당 조절과 관련된 비용과 합병증을 잠재적으로 줄일 수 있습니다. 이 기술은 미주신경 조절, 혈당 조절, AI 및 블루투스 응용 프로그램과 관련된 62개의 발행 또는 대기 중인 특허로 구성된 강력한 지적 재산 포트폴리오에 의해 뒷받침됩니다.
전임상 개발이 완료되었으며, Zucker 쥐 모델과 알로크산 처리된 돼지 모델에서 모두 혈당 조절이 향상되었음을 보여주었습니다. 이 기술은 간과 췌장에 대한 미주신경 차단 및 자극을 선택적으로 조절하여 작동합니다.
ReShape Lifesciences (RSLS) a obtenu le brevet numéro 277949 en Israël pour sa technologie de neuromodulation du diabète, offrant une protection jusqu'au 4 décembre 2039. La technologie combine la plateforme propriétaire de blocage du nerveux vague (vBloc™) de l'entreprise avec la stimulation du nerveux vague pour traiter le diabète de type 2.
Le système vise à réduire la dépendance des diabétiques aux médicaments grâce à un traitement personnalisé, ce qui pourrait potentiellement diminuer les coûts et les complications associées à un mauvais contrôle de la glycémie. La technologie est soutenue par un solide portefeuille de propriété intellectuelle de 62 brevets délivrés ou en attente, liés à la neuromodulation vagale, au contrôle de la glycémie, à l'IA et aux applications Bluetooth.
Le développement préclinique est achevé, montrant une augmentation du contrôle glycémique à la fois chez des modèles de rats Zucker et des modèles porcins traités à l'alloxane pour le diabète de type 2 (T2DM). La technologie fonctionne en modulant sélectivement le blocage et la stimulation vagale du foie et du pancréas.
ReShape Lifesciences (RSLS) hat das Patent Nr. 277949 in Israel für seine Technologie zur Neuromodulation von Diabetes erhalten, die bis zum 4. Dezember 2039 Schutz bietet. Die Technologie kombiniert die proprietäre Vagusnerv-Blockierungsplattform (vBloc™) des Unternehmens mit der Vagusnerv-Stimulation zur Behandlung von Typ-2-Diabetes.
Das System zielt darauf ab, die Medikamentenabhängigkeit von Diabetikern durch personalisierte Behandlung zu reduzieren, was möglicherweise die Kosten und Komplikationen im Zusammenhang mit einer schlechten Blutzuckerkontrolle senken könnte. Die Technologie wird von einem soliden Portfolio an geistigem Eigentum mit 62 erteilten oder anhängigen Patenten im Zusammenhang mit vagaler Neuromodulation, Blutzuckerkontrolle, KI und Bluetooth-Anwendungen unterstützt.
Die präklinische Entwicklung wurde abgeschlossen und zeigte eine erhöhte glykämische Kontrolle sowohl in Zucker-Ratten- als auch in mit Alloxan behandelten Schweinemodellen für Typ-2-Diabetes mellitus (T2DM). Die Technologie funktioniert durch selektive Modulation der Vagusnervblockade und -stimulation in der Leber und der Bauchspeicheldrüse.
- Patent protection secured until December 2039 in Israel
- Strong IP portfolio with 62 issued or pending patents
- Successful completion of pre-clinical development
- Demonstrated positive results in animal models
- Technology still in pre-clinical phase, far from commercialization
- No human trial data available yet
Insights
The Israeli patent grant for ReShape's Diabetes Neuromodulation technology marks a strategic expansion of their intellectual property portfolio in the $63 billion global Type 2 diabetes treatment market. The technology's dual-action approach - combining vagal nerve blocking with stimulation - represents a potentially disruptive innovation in diabetes management.
The pre-clinical results in both Zucker rat and alloxan-treated swine models are particularly noteworthy, as these are gold-standard animal models for testing diabetes interventions. The successful demonstration of glycemic control in these models suggests a robust proof-of-concept, though the path to human trials and eventual commercialization will require significant additional validation.
What sets this technology apart is its personalized approach to glucose management through bioelectronic modulation of the vagus nerve's influence on the liver and pancreas. This could potentially address one of the major challenges in current diabetes treatment: medication non-compliance and the associated complications. The technology's ability to reduce medication dependence could translate to substantial cost savings in diabetes management, where annual per-patient costs can exceed
The patent protection until 2039 provides ReShape with a 16-year runway to develop and commercialize this technology. Their extensive IP portfolio of 62 patents related to vagal neuromodulation, glucose control and AI applications creates significant barriers to entry and positions them strongly for potential partnerships or licensing agreements in the diabetes space.
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia
IRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent Number 277949, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control Systems and Methods,” will provide protection until December 4, 2039. The Diabetes Neuromodulation system utilizes its proprietary vagus nerve block (vBloc™) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity.
“Granting of this key international patent is a testament to this innovative technology, which has demonstrated the ability to reduce the reliance on medications for diabetics in a personalized manner, aiming to lower treatment costs and complications associated with poorly controlled blood glucose and medication non-compliance,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “As with other patent families within ReShape, the Diabetes Neuromodulation technology is backed by a strong intellectual property portfolio of 62 issued or pending patents related to vagal neuromodulation, glucose control, AI and Bluetooth applications to ensure a path to commercialization and the ability to defend this patent portfolio against any competitive threats.”
“Type 2 diabetes is a global problem and remains challenging to effectively treat, despite medication, surgery and diet,” stated Jonathan Waataja, Ph.D. Director of Research at ReShape Lifesciences. “ReShape’s Diabetes Neuromodulation technology manages blood glucose by selectively modulating vagal block and stimulation to the liver and pancreas. We have demonstrated increased glycemic control in a Zucker rat model of Type 2 Diabetes Mellitus (T2DM) as well as in an alloxan treated swine model of T2DM. To date, our team has successfully completed the pre-clinical development of the device, utilizing bioelectronics to optimize insulin production and manage blood glucose levels in a personalized way for the potential treatment of Type 2 diabetes and hypoglycemia.”
About The ReShape Diabetes Neuromodulation Device
The ReShape Diabetes Neuromodulation system (formerly, Diabetes Bloc-Stim Neuromodulation™ (DBSN™) is a novel minimally invasive therapeutic implant concept that delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The system utilizes a proprietary, reversable and adjustable electrical blockade that may represent the future of personalized medicine. Reshape Lifesciences believes the system is superior to both standalone stimulation of the vagus nerve that has shown mixed results.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® and Lap-Band® 2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band® System, Obalon® Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the DBSN™ system will be owned by Biorad.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our continued development of the DBSN™ system and the potential effectiveness of vagal neuromodulation as a treatment for Type 2 Diabetes and metabolic disorders. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com
FAQ
When does ReShape Lifesciences' (RSLS) new diabetes patent in Israel expire?
How many patents does RSLS have for its vagal neuromodulation technology?
What animal models has RSLS tested its Diabetes Neuromodulation technology on?
How does RSLS's Diabetes Neuromodulation technology work?
What stage of development is RSLS's Diabetes Neuromodulation technology in?
